Phase II Study of Durvalumab Combined With Etoposide and Platinum as First Treatment for Advanced Large-cell Neuroendocrine Lung Carcinoma
Led by Centre Leon Berard · Updated on 2024-08-02
80
Participants Needed
31
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Large-cell neuroendocrine carcinomas LCNECs of the lung are rare, aggressive tumors with poor prognosis and limited treatment options. Researchers are evaluating the combination of durvalumab with etoposide and platinum chemotherapy as a first-line treatment to improve the progression-free rate at 12 months in patients with advanced LCNEC confirmed by expert pathologist review. This phase II, multicenter, open-label study aims to assess the efficacy and safety of this combination compared to historical data.
Participants will receive durvalumab combined with etoposide and either cisplatin or carboplatin. Treatment includes an induction phase with cycles every three weeks for 12 weeks four cycles, followed by a maintenance phase with durvalumab every four weeks for up to 24 months. This prospective study uses an external control arm for comparison and focuses on first-line treatment of advanced LCNEC.
During the study, patients will be closely monitored through scheduled visits and assessments, including radiological evaluations to measure disease progression. Researchers will track the progression-free rate at 12 months as the primary outcome and also evaluate objective response rates, disease control rates, overall survival, and safety profiles over a period of up to 63 months. Participants will be followed for adverse events and treatment-emergent effects for up to 27 months and 90 days post-treatment, ensuring comprehensive safety and efficacy evaluation.
CONDITIONS
Brief Title
FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum
Research Team
J
Julien GAUTIER
L
Luc ODIER, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Histological diagnosis of Large-Cell Neuroendocrine Carcinoma of the lung
Sufficient tumor material available for central confirmation and analyses
Locally advanced (Stage III) or metastatic (Stage IV) disease eligible for first-line treatment
Patients with recurrence beyond 3 months after last chemotherapy are eligible
Measurable disease according to RECIST 1.1 criteria
Eastern Cooperative Oncology Group performance status of 0 or 1
Body weight greater than 30 kilograms
Life expectancy of at least 12 weeks
Adequate organ and marrow function per specified laboratory values
Female patients must be post-menopausal or have negative pregnancy tests
Use of highly effective contraception during treatment and specified post-treatment periods
Willingness and ability to comply with study procedures and visits
Affiliation to a social security system
Ability to provide signed informed consent
You will not qualify if you...
Concurrent enrollment in another interventional clinical study, except observational or during follow-up period
Previous treatment for metastatic LCNEC
Prior use of PD1 or PD-L1 inhibitors including durvalumab
Use of concurrent chemotherapy, investigational products, biologics, or hormonal cancer therapies
Major surgery within 21 days prior to first study drug dose
History of allogenic organ transplantation
Active or prior autoimmune or inflammatory disorders, except specified exceptions
Uncontrolled illnesses such as infections, heart failure, unstable angina, or psychiatric conditions limiting compliance
History of other primary malignancies unless meeting specific remission criteria
Central nervous system metastases unless stable and asymptomatic
Carcinomatous meningitis
QTcF interval greater than 470 ms
History of active primary immunodeficiency
Active hepatitis B or C infections, HIV positive, or active tuberculosis
Recent use of immunosuppressive medication except specified exceptions
Receipt of live attenuated vaccine within 30 days prior to first dose
Known allergy or hypersensitivity to study drugs or excipients
Pregnancy or breastfeeding woman
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 12 weeks for induction phase and up to 24 months for maintenance phase
Participants receive a combination of durvalumab with etoposide and platinum chemotherapy as first-line treatment for Large-cell Neuroendocrine Carcinoma of the lung.
Every 3 weeks for 12 weeks during induction (4 cycles) and every 4 weeks for up to 24 months during maintenance
Follow-up
Duration - Up to 27 months and 90 days post-treatment
Participants are monitored for safety and overall survival following treatment completion.
Visits scheduled as per safety monitoring requirements
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Phase II Study of Durvalumab Combined With Etoposide and Platinum as First Treatment for Advanced Large-cell Neuroendocrine Lung Carcinoma
Open-label Phase I Study Evaluating Safety and Activity of 225Ac-ETN029 in Adults With Advanced DLL3-positive Solid Tumors
Study of Tarlatamab Combined With Radiation Therapy in Patients With DLL3-Expressing Tumors Including Small Cell Lung Cancer
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Development of an externally controlled trial from a single-arm study to assess first-line immunochemotherapy in advanced large cell neuroendocrine lung carcinomas: a study protocol from the FIRST-NEC GFPC 01-2022 trial.
Aymeric De Montfort, David Pérol, Audrey Lupo-Mansuet...